UroGen Pharma Ltd.
URGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $654 | $524 | $501 |
| - Cash | $90 | $93 | $104 | $172 |
| + Debt | $128 | $126 | $125 | $123 |
| Enterprise Value | – | $687 | $545 | $452 |
| Revenue | $27 | $0 | $20 | $25 |
| % Growth | – | -100% | -17.5% | – |
| Gross Profit | $24 | $0 | $18 | $22 |
| % Margin | 88.1% | – | 88.5% | 89.9% |
| EBITDA | -$26 | $0 | -$39 | -$26 |
| % Margin | -93.8% | – | -192% | -107.8% |
| Net Income | -$33 | $0 | -$44 | -$38 |
| % Margin | -121.3% | – | -216.5% | -152.7% |
| EPS Diluted | -0.69 | -1.05 | -0.92 | -0.8 |
| % Growth | 34.3% | -14.1% | -15% | – |
| Operating Cash Flow | -$42 | -$40 | -$42 | -$14 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$42 | -$40 | -$42 | -$14 |